Abbvie
1Q Revenues: $12.2 billion (-10%)
1Q Earnings: $241 million (earnings were $4.5 billion in 1Q22)
Comments: Revenues from the Immunology Portfolio were $5.6 billion, down 9%. Global Humira sales were $3.5 billion in the quarter, down 25%. Global Skyrizi sales were $1.4 billion, up 45%. Global Rinvoq sales were $686 million, up 48%. Revenues from the Hematologic Oncology Portfolio were $1.4 billion, down 14%, with Imbruvica revenues of $878 million, down 25%, and Venclexta sales of $538 million, up 14%. Global revenues from the Neuroscience Portfolio were $1.7 billion, up 14%, with Botox Therapeutic revenues up 17% to $719 million and Vraylar revenues up 31% to $561 million. Global revenues from the Aesthetics Portfolio were $1.3 billion, down 5%; Global Botox Cosmetic sales $659 million, up 3%. Global Juvederm sales were down 13% to $355 million. Reported earnings for the three months ended March 31, 2023 included acquired IPR&D and milestones expense of $150 million.